Proud to be involved with this important ESMO - Eur. Oncology consensus statement. Do check out the section on stage 3 EGFRm NSCLC #LCSM Annals of Oncology

doi.org/10.1016/j.jtho…

Pembrolizumab Maintains Survival Benefits in 4-year Follow-Up of KEYNOTE-042 in NSCLC in China onclive.com/view/pembroliz… via @onclive

Our review Perioperative Target Therapy for Oncogene-Driven NSCLC online on LUNG CANCER

🌟ONLINE NOW Lung Cancer Journal “ “Perioperative targeted therapy for oncogene-driven NSCLC” by Thomas Wu et al #LCSM 🟥Read it here: lungcancerjournal.info/action/showPdf…

Consolidation Sugemalimab Provides Sustained PFS Benefit in Unresectable Stage III NSCLC onclive.com/view/consolida… via @onclive The first phase 3 trial showed that sCRT followed by sugemalimab could give stage 3 unresectable patients survival benefit.

Researchers highlighted new #lungcancer study data from around the world during #WCLC22. Catch up on those presentations in ILCN: ow.ly/aKcn50KgltS #LCSM

ESMO IO Proffered Paper session <small>(ID 21)</small> cslide.ctimeetingtech.com/immuno22hybrid…

dailyreporter.esmo.org/esmo-immuno-on… Neoadjuvant PD1-TGF with chemo better than PD1-TGF mono in PD-L1>50% NSCLC and 25.2% surgery conversion in 3A-3C unresectable NSCLC.

Did you know IASLC members receive special access to the IASLC’s virtual libraries for all meetings including previous WCLC’s and other IASLC meetings? JOIN or RENEW today! bit.ly/3Fy6otr #LCSM

x.com/IASLC/status/1…

Neoadjuvant SHR-1701 Increases Response, Resectability in Stage III Unresectable NSCLC onclive.com/view/neoadjuva… via @onclive

Our review in rdcu.be/dagfs Emerging evidence and treatment paradigm of non-small cell lung cancer

Treatment of patients with HER2-mutant non-small cell lung cancer with pyrotinib in a phase 2 trial or compassionate use showed a favourable objective response rate, while patients treated in parallel by physician's choice in a real-world study did not. nature.com/articles/s4159…

Our paper on First-line pyrotinib in advanced HER2+NSCLC: a patient-centric phase 2 trial rdcu.be/dhCoA. online at Nature Medicine. Thanks Drs. Grant and Goldberg for your comments: "Precise, pragmatic and inclusive: the modern era of oncology clinical trials.

🎙️ Early undetectable ctDNA during CRT 🔁⬆️OS in #lungcancer‼️OncoAlert 📌Retro study of 761 blood samples from 139 👥 undergoing RT 🥇🎯: Study on ctDNA during chemoradiotherapy (CRT) in #nonsmall cell lung cancer RESULTs📊 👉ctDNA levels ⬇️ significantly during CRT at on-RT

Our Editorial for FLAURA 2 just published NEJM online. DOI: 10.1056/NEJMe2311559

Our paper just out on Cancer Cell: IO inductive therapy let 25% unresectable stage 3 NSCLC become resectable and more patients without recurrence than that received CCRT. Thanks all investigators from 15 sites in China. It is impossible without their hard works!

Great